# Imatinib

## Leevk 100mg

##### 

| TAH Drug Code      | OLEEV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Adult & pediatrics with newly diagnosed chronic myeloid leukemia (CML), CML in blast crisis, accelerated phase or chronic phase after failure of interferon-α therapy. Adult with newly diagnosed Philadelphia chromosome +ve acute lymphoblastic leukemia (Ph+ALL) integrated with chemotherapy; with relapsed or refractory Ph+ALL as montherapy; myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements; systemic mastocytosis (SM) without D816V c-Kit mutation or with c-Kit mutation status unknown; hypereosinophilic syndrome (HES) &/or chronic eosinophilic leukemia (CEL); unresectable &/or metastatic, malignant GI stromal tumors (GIST); unresectable, recurrent &/or dermatofibrosarcoma protuberans (DFSP).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | [Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)]- Chronic phase: 400 mg once daily, may be increased to 600 mg daily- Accelerated phase or blast crisis: 600 mg once daily, may be increased to 800 mg daily (400 mg twice daily) [Ph+ acute lymphoblastic leukemia (ALL)] 600 mg once daily [Myelodysplastic/myeloproliferative disease (MDS/MPD)] 400 mg once daily [Aggressive systemic mastocytosis (ASM) associated with eosinophilia] Initiate at 100 mg once daily; if assessments demonstrate insufficient response, increase from 100-400 mg/day in the absence of adverse reactions. [ASM without D816V c-Kit mutation or c-Kit mutation status unknown] 400 mg once daily [Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL)] 400 mg once daily [HES/CEL with FIP1L1-PDGFRα fusion kinase] Initiate at 100 mg once daily; if assessments demonstrate insufficient response, increase from 100-400 mg/day in the absence of adverse reactions. [Gastrointestinal stromal tumors (GIST)]- Adjuvant treatment following complete resection: 400 mg once daily; recommended treatment duration: 3 years- Unresectable and/or metastatic malignant: 400 mg once daily; may be increased up to 800 mg daily (400 mg twice daily), if tolerated, for disease progression. [Dermatofibrosarcoma protuberans (DFSP)] 400-800 mg/day (400 mg once or twice daily) |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Hypersensitivity to imatinib or any component of the formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | GI disturbances, anorexia, gastro-esophageal reflux, mouth ulceration, myalgia, muscle cramps, joint swelling, headache, dizziness, taste disturbance, paraesthesia, insomnia, conjunctivitis, increased lacrimation, blurred vision, epistaxis, dyspnea, weight gain, periorbital edema, dermatitis, rash, face & eyelid edema, pruritus, erythema, dry skin, alopecia, night sweats, fluid retention & edema, fatigue; pyrexia, weakness, rigors; neutropenia & febrile neutropenia, thrombocytopenia, anemia. Cardiovascular: Edema (1.1% to 86.1% ) Dermatologic: Night sweats (13% to 17% ), Rash (up to 49.8% ) Endocrine metabolic: Weight gain (up to 32% ) Gastrointestinal: Diarrhea (3% to 58.2% ), Nausea (3% to 73% ), Vomiting (2% to 58% ) Musculoskeletal: Arthralgia (12.3% to 40% ), Cramp (up to 62% ), Musculoskeletal pain (up to 49% ), Myalgia (9% to 32.2% ) Neurologic: Asthenia (15% to 21% ), Dizziness (12% to 16% ), Headache (up to 36% ), Insomnia (10% to 14% ) Respiratory: Cough (14% to 27% ), Nasopharyngitis (10% to 30.5% ), Pain, Pharyngolaryngeal (18.1% ), Pharyngitis (10% to 15% ) Other: Fatigue (25% to 48% ), Fever (16.7% to 41% ), Influenza (0.8% to 13.8% ), Rigor (10% to 12% )                                                                                                                                                                                 |
| Pregnancy          | Human (and Animal) Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

